search
Back to results

Effects of Topical Lidocaine During Urodynamic Testing In Women

Primary Purpose

Urinary Stress Incontinence, Pain

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
lidocaine 2% gel
water soluble lubricant
Sponsored by
Kristine Zinkgraf
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Urinary Stress Incontinence focused on measuring urodynamics, women, lidocaine gel

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

Women with complaint of stress urinary incontinence who were scheduled for a urodynamic test Patients with symptomatic pelvic organ prolapse if they also had stress incontinence symptoms.

Community dwelling elderly patients who were able to provide their own history and were able to sign for themselves

Exclusion Criteria:

Patients who were unable to provide their own consent Patients who are allergic to lidocaine Children and pregnant patients

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Placebo Comparator

    Active Comparator

    Arm Label

    Placebo Lubricant Gel

    Lidocaine 2% Gel

    Arm Description

    5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion

    5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion

    Outcomes

    Primary Outcome Measures

    Change in pain immediately after urethral pressure profilometry
    Patient rated pain using Likert Scale of 0-10 (0 is no pain and 10 is worst pain)

    Secondary Outcome Measures

    Demonstration of stress urinary incontinence during the urodynamic test
    Ability to demonstrate stress urinary incontinence during the urodynamic test
    Perception of bladder filling
    Correlation of maximal cystometric capacity on urodynamic test and maximal voided volume on bladder diary

    Full Information

    First Posted
    February 15, 2019
    Last Updated
    March 15, 2019
    Sponsor
    Kristine Zinkgraf
    Collaborators
    Medical College of Wisconsin, WomenConnected
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03881293
    Brief Title
    Effects of Topical Lidocaine During Urodynamic Testing In Women
    Official Title
    Effects of Topical Lidocaine During Urodynamic Testing In Women
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    December 2013 (Actual)
    Primary Completion Date
    December 2016 (Actual)
    Study Completion Date
    December 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Kristine Zinkgraf
    Collaborators
    Medical College of Wisconsin, WomenConnected

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Urodynamic testing is used to help diagnose causes of urinary incontinence and voiding dysfunction. The purpose of the urodynamic test is to gain insight into the patient's urinary symptoms and assist in making a diagnosis. Catheter insertion and manipulation during the test can be uncomfortable for the patient. Lidocaine gel has not been used routinely during urodynamic testing. However, it is used routinely during outpatient cystoscopy and with any urethral catheterization. The investigators proposed that lidocaine numbing gel could be used without compromising test findings. The study included 110 adult women. The purpose was: Determine whether the use of topical lidocaine during urodynamic testing decreases patient discomfort during the procedure. Evaluate whether the use of topical lidocaine affects the urodynamic results.
    Detailed Description
    Topical Lidocaine For Urodynamic Testing: A Double Blinded Randomized Control Trial Hypothesis / aims of study Determine whether the use of topical lidocaine during urodynamic testing decreases patient discomfort during the procedure. Evaluate whether the use of topical lidocaine affects the urodynamic results. Study design, materials and methods The hospital IRB approved the study. Women with symptoms of stress urinary incontinence (SUI) scheduled for a urodynamic study (UDS) were eligible to participate. Women presenting with predominant overactive bladder symptoms were excluded. Participants were randomized on the day of the procedure using Random Allocation Software Version 1.0. All were blinded to the study arms until completion of final data analysis. Participant randomization assignment was known only to an independent research nurse and the dispensing pharmacist. The study consisted of transurethral administration of 5 ml lidocaine 2% gel or surgilube gel, in the study and control arms, respectively, 10 minutes before catheter insertion. Prior to testing, a 24 hour bladder diary and the Pelvic Floor Distress Inventory - Short Form 20 were completed. During the UDS participants were asked for sensory information including desire to void and maximal cystometric capacity (MCC). Urethral pressure profiles were obtained at an infused volume of 200 ml. Provocative measures were performed to assess SUI. Using a Likert scale, pain was assessed prior to and after catheter insertion, after performing the urethral pressure profile, and at the completion of the study. The primary outcome; pain after urethral pressure profile (UPP), was compared between the two groups. Comparisons of the bladder diary and UDS results were made between study and control arms individually and in-between groups. Statistical methods The effect of lidocaine on patient pain as reported during multiple time-points during the UDS was evaluated using repeated measures analysis via mixed effects regression with a random patient-specific intercept. This approach allows the evaluation of the overall pain experience, as well as baseline-adjusted comparison at individual time-points. Comparisons were done using t-tests for continuous variables, Chi-squared test for categorical variables, Wilcoxon rank-sum test, Lin's Concordance Correlation Coefficient (CCC), and a z-test. The CCC provides a generalization of Pearson's correlation coefficient that measures how well the data align with the diagonal representing equal values for the two measurements (as opposed to any straight line). Agreement is stronger than correlation. Specifically, the agreement between mean void volume and volume at strong desire, as well as between maximum void volume and volume at MCC were computed separately for each study group. The CCC values were compared between the study groups using a z-test. Power calculations determined a total sample size of 110 participants was needed to detect significant differences between the groups with at least 94% statistical power.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Urinary Stress Incontinence, Pain
    Keywords
    urodynamics, women, lidocaine gel

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Double Blinded Randomized Control Trial
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    110 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Placebo Lubricant Gel
    Arm Type
    Placebo Comparator
    Arm Description
    5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion
    Arm Title
    Lidocaine 2% Gel
    Arm Type
    Active Comparator
    Arm Description
    5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion
    Intervention Type
    Drug
    Intervention Name(s)
    lidocaine 2% gel
    Intervention Description
    Transurethral instillation of 5 ml lidocaine 2% gel
    Intervention Type
    Drug
    Intervention Name(s)
    water soluble lubricant
    Intervention Description
    Transurethral instillation of 5 ml water soluble lubricant
    Primary Outcome Measure Information:
    Title
    Change in pain immediately after urethral pressure profilometry
    Description
    Patient rated pain using Likert Scale of 0-10 (0 is no pain and 10 is worst pain)
    Time Frame
    Pain was assessed immediately after urethral pressure profilometry was performed
    Secondary Outcome Measure Information:
    Title
    Demonstration of stress urinary incontinence during the urodynamic test
    Description
    Ability to demonstrate stress urinary incontinence during the urodynamic test
    Time Frame
    During the urodynamic test
    Title
    Perception of bladder filling
    Description
    Correlation of maximal cystometric capacity on urodynamic test and maximal voided volume on bladder diary
    Time Frame
    During the urodynamic test

    10. Eligibility

    Sex
    Female
    Gender Based
    Yes
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Women with complaint of stress urinary incontinence who were scheduled for a urodynamic test Patients with symptomatic pelvic organ prolapse if they also had stress incontinence symptoms. Community dwelling elderly patients who were able to provide their own history and were able to sign for themselves Exclusion Criteria: Patients who were unable to provide their own consent Patients who are allergic to lidocaine Children and pregnant patients
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Katherine Stevenson, MD
    Organizational Affiliation
    ProHealth Care
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Effects of Topical Lidocaine During Urodynamic Testing In Women

    We'll reach out to this number within 24 hrs